Biography:Nitzan Rosenfeld
Nitzan Rosenfeld | |
|---|---|
| Alma mater | Weizmann Institute of Science. |
| Scientific career | |
| Institutions | Cancer Research UK Cambridge Institute, University of Cambridge, Inivata |
| Website | www |
Nitzan Rosenfeld FMedSci is a professor of Cancer Diagnostics at the University of Cambridge. He is a Senior Group Leader at the Cancer Research UK Cambridge Institute and co-founder of Inivata, a clinical cancer genomics company.
Education
Nitzan trained in Physics, and specialized in quantitative molecular biology, obtaining a Ph.D. in the field of Systems Biology from the Weizmann Institute of Science.[1]
Research and career
After completing his Ph.D., Rosenfeld began working in translational research within Rosetta Genomics Ltd, a leading company in microRNA-based diagnostic tests for cancer.[2]
In 2009 he joined the Cancer Research UK Cambridge Institute at the University of Cambridge. Within his first year, his laboratory became one of the few worldwide to obtain accurate data on circulating tumour DNA (ctDNA) in patient plasma.[3]
His team was first to develop and demonstrate effective methods of gene panel sequencing of cell-free plasma DNA.[4] They went on to demonstrate the utility of exome-wide sequencing for analysis of ctDNA.[5]
Targeted sequencing of plasma DNA has since become widely used in cancer research and diagnostics. His team and clinical collaborators demonstrated the ability to use ctDNA to study tumour heterogeneity and evolution,[6] and provided key evidence for the utility of ctDNA in monitoring cancer response and progression.[7]
Their key publication in the New England Journal of Medicine demonstrated the advantages of ctDNA over other biomarkers, notably circulating tumor cells.[8] These accumulated achievements played a significant role in the explosive growth of the ctDNA field.[9]
Rosenfeld is the co-founder and Chief Scientific Officer of Inivata Ltd., one of the UK's leading genomics companies that was amongst the first to offer clinical liquid biopsy tests for cancer genomic profiling.[10]
Awards and honours
In 2013, Professor Rosenfeld was awarded the Cancer Research UK Future Leaders in Cancer Research Prize and the British Association for Cancer Research Translational Research Award.[11]
He was awarded the Foulkes Foundation Medal in 2015 from the Academy of Medical Sciences for outstanding bioscience research.[3]
Rosenfeld was awarded the 2020 Pezcoller Foundation – EACR Cancer Researcher Award, celebrating academic excellence and achievements in the field of translational cancer research.[12]
He was elected Fellow of the Academy of Medical Sciences[13] in 2020. His citation on election reads:
"Nitzan Rosenfeld is a Senior Group Leader at Cancer Research UK Cambridge Institute. He is a pioneer and world leader in developing liquid biopsy tests for cancer using circulating tumour DNA. He has developed multiple clinical diagnostic tests for cancer, based on microRNA expression profiling and on circulating cell-free tumour DNA in plasma. He co-founded Inivata Ltd., one of the UK's leading genomics companies that was amongst the first to offer clinical liquid biopsy tests for cancer genomic profiling. His research group continues to develop sensitive methods for detection of cell free tumour DNA in body fluids, and ways to apply these for cancer detection and monitoring."
References
- ↑ "SELECTBIO – Exosomes and Microvesicles Speaker Biography". https://selectbiosciences.com/conferences/biographies.aspx?conf=ev2015&speaker=1314480.
- ↑ Ltd, Rosetta Genomics (2007-04-12). "Rosetta Genomics to Present Advancements in Its Cup Diagnostic Development Program". GlobeNewswire News Room (Press release). Retrieved 2023-03-17.
- ↑ 3.0 3.1 "Foulkes Medal 2015 awarded to Dr Nitzan Rosenfeld". https://acmedsci.ac.uk/more/news/foulkes-medal-2015-awarded-to-dr-nitzam-rosenfeld.
- ↑ Forshew, Tim; Murtaza, Muhammed; Parkinson, Christine; Gale, Davina; Tsui, Dana W. Y.; Kaper, Fiona; Dawson, Sarah-Jane; Piskorz, Anna M. et al. (2012-05-30). "Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA" (in en). Science Translational Medicine 4 (136): 136ra68. doi:10.1126/scitranslmed.3003726. ISSN 1946-6234. PMID 22649089. https://www.science.org/doi/10.1126/scitranslmed.3003726.
- ↑ Murtaza, Muhammed; Dawson, Sarah-Jane; Tsui, Dana W. Y.; Gale, Davina; Forshew, Tim; Piskorz, Anna M.; Parkinson, Christine; Chin, Suet-Feung et al. (2013). "Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA" (in en). Nature 497 (7447): 108–112. doi:10.1038/nature12065. ISSN 0028-0836. PMID 23563269. Bibcode: 2013Natur.497..108M. http://www.nature.com/articles/nature12065.
- ↑ Murtaza, Muhammed; Dawson, Sarah-Jane; Pogrebniak, Katherine; Rueda, Oscar M.; Provenzano, Elena; Grant, John; Chin, Suet-Feung; Tsui, Dana W. Y. et al. (2015-11-04). "Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer" (in en). Nature Communications 6 (1): 8760. doi:10.1038/ncomms9760. ISSN 2041-1723. PMID 26530965. Bibcode: 2015NatCo...6.8760M.
- ↑ Parkinson, Christine A.; Gale, Davina; Piskorz, Anna M.; Biggs, Heather; Hodgkin, Charlotte; Addley, Helen; Freeman, Sue; Moyle, Penelope et al. (2016-12-20). Mardis, Elaine Rene. ed. "Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study" (in en). PLOS Medicine 13 (12): e1002198. doi:10.1371/journal.pmed.1002198. ISSN 1549-1676. PMID 27997533.
- ↑ Dawson, Sarah-Jane; Tsui, Dana W.Y.; Murtaza, Muhammed; Biggs, Heather; Rueda, Oscar M.; Chin, Suet-Feung; Dunning, Mark J.; Gale, Davina et al. (2013-03-28). "Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer" (in en). New England Journal of Medicine 368 (13): 1199–1209. doi:10.1056/NEJMoa1213261. ISSN 0028-4793. PMID 23484797.
- ↑ "2020 - NITZAN ROSENFELD". http://www.pezcoller.it/en/awards/the-pezcoller-foundation-–-eacr-translational-cancer-researcher-award/2020---nitzan-rosenfeld/.
- ↑ "Leadership Team" (in en-US). https://www.inivata.com/about-us/leadership-team/.
- ↑ admin, C. P. L. (2013-06-24). "Nitzan Rosenfeld receives British Association for Cancer Research Translational Research Award" (in en-GB). https://www.cruk.cam.ac.uk/2013/06/24/congratulations-to-nitzan-rosenfeld.
- ↑ "The Pezcoller Foundation-EACR Translational Cancer Researcher Award | The European Association for Cancer Research". https://www.eacr.org/pezcoller-foundation-awards/translational-cancer-researcher-award.
- ↑ "Prof. Nitzan Rosenfeld | The Academy of Medical Sciences". https://acmedsci.ac.uk/fellows/fellows-directory/ordinary-fellows/fellow/Nitzan-Rosenfeld-0033z00002qIKKHAA4.
 |  |
